A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid
synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as
an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK
activator or a farnesyl pyrophosphoric acid synthase preparation;
utilization thereof; a method therefor; a blood vessel remedy comprising
the nuclear transfer promoter for Cdc42 protein as the active ingredient;
and a method of screening a blood vessel remedy which comprises assaying
the ability of Cdc42 protein to transfer into nucleus.